NYSE:TDOC - Teladoc Stock Price, Price Target & More

Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc Inc (NYSE:TDOC) released its quarterly earnings results on Tuesday, May, 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.04. The health services provider had revenue of $89.64 million for the quarter, compared to the consensus estimate of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The company's revenue for the quarter was up 109.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) EPS. View Teladoc's Earnings History.

Teladoc is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Teladoc.

Teladoc updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of ($1.41-1.36) for the period, compared to the Thomson Reuters consensus EPS estimate of ($1.35). The company issued revenue guidance of $350-360 million, compared to the consensus revenue estimate of $356.28 million.Teladoc also updated its Q2 guidance to ($0.37-0.35) EPS.

18 Wall Street analysts have issued 12-month price targets for Teladoc's shares. Their forecasts range from $39.00 to $80.00. On average, they anticipate Teladoc's share price to reach $55.50 in the next twelve months. This suggests that the stock has a possible downside of 21.2%. View Analyst Ratings for Teladoc.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Teladoc include UCB S A/ADR (UCBJY), ResMed (RMD), Smith & Nephew (SNN), Cardinal Health (CAH), Quest Diagnostics (DGX), UCB (UCBJF), Incyte (INCY), GRIFOLS S A/S (GRFS), H. Lundbeck A/S- (HLUYY), IPSEN S A/S (IPSEY), OLYMPUS Corp/S (OCPNY), Novozymes A/S (NVZMF), Merck KGaA (MKGAF), GENMAB A/S/S (GMXAY) and Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC).

(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Press coverage about TDOC stock has been trending somewhat negative recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teladoc earned a news sentiment score of -0.15 on Accern's scale. They also gave media headlines about the health services provider an impact score of 48.72 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Teladoc's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (1.40%), Summit Partners L P (1.04%), Baillie Gifford & Co. (0.98%), Peregrine Capital Management LLC (0.60%), Fred Alger Management Inc. (0.12%) and Handelsbanken Fonder AB (0.07%). Company insiders that own Teladoc stock include Adam C Vandervoort, Andrew Turitz, James K Outland, Jason N Gorevic, Lewis Levy, Lp Chp III, Mark Hirschhorn, Michael Goldstein, Michael H King, Peter A Mcclennen and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc.

TDOC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Riverbridge Partners LLC. Company insiders that have sold Teladoc company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein and Peter A Mcclennen. View Insider Buying and Selling for Teladoc.

TDOC stock was purchased by a variety of institutional investors in the last quarter, including Summit Partners L P, Baillie Gifford & Co., Fred Alger Management Inc., Handelsbanken Fonder AB, Calamos Advisors LLC, Daiwa SB Investments Ltd., Benjamin F. Edwards & Company Inc. and Garner Asset Management Corp. View Insider Buying and Selling for Teladoc.

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TDOC stock can currently be purchased for approximately $70.40.

Teladoc has a market capitalization of $4.26 billion and generates $233.28 million in revenue each year. The health services provider earns $-106,780,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Teladoc employs 1,231 workers across the globe.

Teladoc's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]